Darling Ingredients’ Health Brand Rousselot Receives U.S. Patent for Nextida® GC, the First Collagen Peptide Composition Supporting Blood Glucose Regulation
Darling Ingredients’ Health Brand Rousselot Receives U.S. Patent for Nextida® GC, the First Collagen Peptide Composition Supporting Blood Glucose Regulation
Collagen peptides are short chains of protein building blocks made by breaking down collagen, the structural protein that gives skin, bone and connective tissue strength; think of them as smaller Lego pieces taken from a larger structure so the body can absorb them more easily. Investors care because these peptides are sold as ingredients in supplements, foods and cosmetics, so demand, safety rules, clinical claims and production costs can directly affect revenue and profit margins for companies that make or use them.
dietary supplementmedical
A dietary supplement is a product taken by mouth that adds nutrients or other ingredients—such as vitamins, minerals, herbs, amino acids, or enzymes—to the diet; it is intended to support normal bodily functions, not to diagnose, treat, cure, or prevent disease. Investors care because these products sit between food and drugs in regulation, so sales, branding, quality control, labeling claims and regulatory scrutiny can drive demand, margins, recalls and legal risk much like a fast-moving consumer staple.
blood glucosemedical
Blood glucose is the amount of sugar circulating in the bloodstream that the body uses for energy; it rises after eating and falls between meals or with exercise. For investors, blood glucose is a key clinical metric that drives demand, regulatory decisions, and pricing for drugs, devices and tests related to diabetes and metabolic health—think of it as a fuel gauge that signals market need and product effectiveness.
metabolic supportmedical
Metabolic support describes treatments, supplements or interventions designed to help the body’s chemical processes that turn food into energy, repair tissues and maintain balance. For investors, it signals a product or therapy category with potential demand and regulatory scrutiny: promising results can drive sales and valuations like giving a struggling engine better fuel, while weak evidence or safety issues can create commercial and legal risks.
U.S. Patent and Trademark Office (USPTO)regulatory
The U.S. Patent and Trademark Office (USPTO) is the federal agency that grants patents for inventions and registers trademarks for brand names and logos, acting like a national property office for ideas and brands. For investors it matters because issued patents and registered trademarks can create legal exclusivity, protect market share, enable licensing revenue, and affect a company’s valuation and risk of costly disputes—similar to owning deeded property for a business’s key assets.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
IRVING, Texas--(BUSINESS WIRE)--
Darling Ingredients Inc. (NYSE: DAR) and its health brand Rousselot today announced that the U.S. Patent and Trademark Office (USPTO) has granted Patent No. US12636339 for Nextida GC, a first-of-its-kind collagen peptide ingredient developed to help support healthy after-meal blood sugar levels, naturally. The patent protects both the production process and the use of Nextida GC as a dietary supplement ingredient, offering a non-pharmaceutical option for managing blood glucose through science-backed nutrition.
“This patent reinforces the scientific foundation behind Nextida GC and highlights Darling Ingredients’ ability to translate its collagen expertise into targeted health solutions,” said Randall C. Stuewe, Chairman and Chief Executive Officer. “As demand grows for natural, non-pharmaceutical approaches to health and wellness, we are strengthening our leadership in collagen peptide health ingredients while building a broader pipeline of Nextida solutions.”
Nextida GC is a collagen peptide composition formulated for dietary supplement applications related to natural glucose control and metabolic support. It is part of an expanding portfolio of collagen products being developed to address distinct functional health needs.
Australia (AU2023279850B2), Europe (EP4498839B1), Japan (JP7751755B2) and China (CN119212574B) have also awarded patents for Nextida GC, with additional patents pending in Brazil, Canada, Colombia, Korea, Mexico, India and Peru.
For more information about Nextida GC and Rousselot’s portfolio of science-backed collagen solutions, visit rousselot.com.
About Rousselot
Rousselot, the health brand of Darling Ingredients, is the global leader in gelatin- and collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical industries. Working in partnership with its global customer base, Rousselot delivers advanced ingredient solutions that enable innovation, excite today's consumers and contribute to public health. Through state-of-the-art operations, extensive technical expertise and sustained scientific research, Rousselot helps customers achieve their goals and create world-class products.
About Darling Ingredients
A pioneer in circularity, Darling Ingredients Inc. (NYSE: DAR) takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about 15% of the world’s animal agricultural by-products, produces about 30% of the world’s collagen (both gelatin and hydrolyzed collagen), and is one of the largest producers of renewable energy. To learn more, visit darlingii.com. Follow us on LinkedIn.
